FDA advisers support OTC use of Sanofi's nasal spray

An FDA advisory panel voted 10-6 in favor of allowing Sanofi's Nasacort AQ nasal spray to be sold without a prescription. If approved, the respiratory allergy drug would be the first over-the-counter intranasal corticosteroid available in the U.S. The AAP, along with other health groups, are opposed to selling these drugs without a prescription, stating that proper monitoring of adverse reactions can only be accomplished in a health care setting.

View Full Article in:

Reuters · Pharmaceutical Business Review Online · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care